Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet® constant-release drug delivery system

Janne Marvola; Hanna Kanerva; Lillian Slot; Maija Lipponen; Tommi Kekki; Heikki Hietanen; Sirpa Mykkänen; Kari Ariniemi; Kai Lindevall; Martti Marvola

doi:10.1016/j.ijpharm.2004.05.022

Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet^® constant-release drug delivery system

Janne Marvola (Corresponding Author), Hanna Kanerva, Lillian Slot, Maija Lipponen, Tommi Kekki, Heikki Hietanen, Sirpa Mykkänen, Kari Ariniemi, Kai Lindevall, Martti Marvola

Research output: Contribution to journal › Article › Scientific › peer-review

22 Citations (Scopus)

Abstract

This paper is a report from a pharmacoscintigraphic study with an Egalet^® constant-release system containing caffeine and natural abundance samarium oxide. First the formulation was tested in vitro to clarify integrity during irradiation in the nuclear reactor. Then six healthy male volunteers were enrolled into the in vivo study. The in vitro release of caffeine obeyed all the time linear zero-order kinetics. The in vivo release of radioactive Sm₂O₃ consisted of three consequent linear phases with different slopes. The release rate was fastest while the product was in the small intestine and slowest when the product was in the descending colon. In terms of the bioavailability of caffeine, the most important factor seemed to be the residence time in the ascending and transverse colon. A long residence time in these sections led to high AUC values for caffeine.

Original language	English
Pages (from-to)	3 - 10
Number of pages	8
Journal	International Journal of Pharmaceutics
Volume	281
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ijpharm.2004.05.022
Publication status	Published - 2004
MoE publication type	A1 Journal article-refereed

Keywords

gamma scintigraphy
neutron activation
samarium
imaging
controlled release
in vitro-in vivo correlation

Access to Document

10.1016/j.ijpharm.2004.05.022

Cite this

Marvola, J., Kanerva, H., Slot, L., Lipponen, M., Kekki, T., Hietanen, H., Mykkänen, S., Ariniemi, K., Lindevall, K., & Marvola, M. (2004). Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet^® constant-release drug delivery system. International Journal of Pharmaceutics, 281(1-2), 3 - 10. https://doi.org/10.1016/j.ijpharm.2004.05.022

@article{4ed855f86dbd415fa317b8264e45ca32,

title = "Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet{\textregistered} constant-release drug delivery system",

abstract = "This paper is a report from a pharmacoscintigraphic study with an Egalet{\textregistered} constant-release system containing caffeine and natural abundance samarium oxide. First the formulation was tested in vitro to clarify integrity during irradiation in the nuclear reactor. Then six healthy male volunteers were enrolled into the in vivo study. The in vitro release of caffeine obeyed all the time linear zero-order kinetics. The in vivo release of radioactive Sm2O3 consisted of three consequent linear phases with different slopes. The release rate was fastest while the product was in the small intestine and slowest when the product was in the descending colon. In terms of the bioavailability of caffeine, the most important factor seemed to be the residence time in the ascending and transverse colon. A long residence time in these sections led to high AUC values for caffeine.",

keywords = "gamma scintigraphy, neutron activation, samarium, imaging, controlled release, in vitro-in vivo correlation",

author = "Janne Marvola and Hanna Kanerva and Lillian Slot and Maija Lipponen and Tommi Kekki and Heikki Hietanen and Sirpa Mykk{\"a}nen and Kari Ariniemi and Kai Lindevall and Martti Marvola",

year = "2004",

doi = "10.1016/j.ijpharm.2004.05.022",

language = "English",

volume = "281",

pages = "3 -- 10",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier B.V.",

number = "1-2",

}

Marvola, J, Kanerva, H, Slot, L, Lipponen, M, Kekki, T, Hietanen, H, Mykkänen, S, Ariniemi, K, Lindevall, K & Marvola, M 2004, 'Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet^® constant-release drug delivery system', International Journal of Pharmaceutics, vol. 281, no. 1-2, pp. 3 - 10. https://doi.org/10.1016/j.ijpharm.2004.05.022

Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet^® constant-release drug delivery system. / Marvola, Janne (Corresponding Author); Kanerva, Hanna; Slot, Lillian et al.
In: International Journal of Pharmaceutics, Vol. 281, No. 1-2, 2004, p. 3 - 10.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet® constant-release drug delivery system

AU - Marvola, Janne

AU - Kanerva, Hanna

AU - Slot, Lillian

AU - Lipponen, Maija

AU - Kekki, Tommi

AU - Hietanen, Heikki

AU - Mykkänen, Sirpa

AU - Ariniemi, Kari

AU - Lindevall, Kai

AU - Marvola, Martti

PY - 2004

Y1 - 2004

N2 - This paper is a report from a pharmacoscintigraphic study with an Egalet® constant-release system containing caffeine and natural abundance samarium oxide. First the formulation was tested in vitro to clarify integrity during irradiation in the nuclear reactor. Then six healthy male volunteers were enrolled into the in vivo study. The in vitro release of caffeine obeyed all the time linear zero-order kinetics. The in vivo release of radioactive Sm2O3 consisted of three consequent linear phases with different slopes. The release rate was fastest while the product was in the small intestine and slowest when the product was in the descending colon. In terms of the bioavailability of caffeine, the most important factor seemed to be the residence time in the ascending and transverse colon. A long residence time in these sections led to high AUC values for caffeine.

AB - This paper is a report from a pharmacoscintigraphic study with an Egalet® constant-release system containing caffeine and natural abundance samarium oxide. First the formulation was tested in vitro to clarify integrity during irradiation in the nuclear reactor. Then six healthy male volunteers were enrolled into the in vivo study. The in vitro release of caffeine obeyed all the time linear zero-order kinetics. The in vivo release of radioactive Sm2O3 consisted of three consequent linear phases with different slopes. The release rate was fastest while the product was in the small intestine and slowest when the product was in the descending colon. In terms of the bioavailability of caffeine, the most important factor seemed to be the residence time in the ascending and transverse colon. A long residence time in these sections led to high AUC values for caffeine.

KW - gamma scintigraphy

KW - neutron activation

KW - samarium

KW - imaging

KW - controlled release

KW - in vitro-in vivo correlation

U2 - 10.1016/j.ijpharm.2004.05.022

DO - 10.1016/j.ijpharm.2004.05.022

M3 - Article

SN - 0378-5173

VL - 281

SP - 3

EP - 10

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 1-2